Epstein Secrets

our amended and restated voting agreement, our directors were elected as follows: Messrs. Dorsey, McKelvey. Khosla, and Johnson and Drs. Summers and Simmons were elected as the designees nominated by holders of our common stock; Mr. Botha was elected as the designee nominated by holders of our Series B

-year terms. Our current directors will be divided among the three classes as follows: • the Class I directors will be Messrs. Dorsey, Johnson, and Viniar, and their terms will expire at the annual meeting of stockholders to be held in 2016: • the Class II directors will be Messrs. Botha and McKelvey

B convertible preferred stock; • Ms. Meeker was elected as the designee nominated by holders of our Series C convertible preferred stock; and • Mr. Viniar was elected as a designee nominated by holders of a majority of each of our common stock and our convertible preferred stock. In connection with th

selected to serve on our board of directors because of her extensive experience advising and analyzing technology companies. Dr. Ruth Simmons. Dr. Simmons has served as a member of our board of directors since August 2015. Dr. Simmons is President Emerita of Brown University, having served as President

from Harvard University. Dr. Summers was selected to serve on our board of directors because of his extensive policy experience. David Viniar. Mr. Viniar has served as a member of our board of directors since October 2013. From August 1980 until his retirement in January 2013, Mr. Viniar served in var

ting schedule as the option. All of the shares vest on January 1, 2016, subject to Mr. Johnson's continued service with us. On August 11, 2015, Dr. Simmons was granted an option to purchase 38,000 shares of our common stock. This option is early exercisable. All of the shares subject to the option vest

mmers' continued service with us. As of December 31, 2014, Dr. Summers held 161,000 restricted shares of our common stock. On October 30, 2013, Mr. Viniar was granted an option to purchase 326,950 shares of our common stock. This option is early exercisable. One-fourth of the shares subject to the opti